Evolution of low HER2 expression between early and advanced-stage breast cancer

Paolo Tarantino, Sara Gandini, Eleonora Nicolò, +11

European Journal of Cancer

Radiation OncologyBreast OncologyMedicineLow Her2 ExpressionBreast Cancer +7

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer

Carmen Criscitiello, Davide Disalvatore, Michelino De Laurentiis, +12

The Breast

Node-positive Breast CancerEndocrine OncologyBreast OncologyHigh Ki-67 ScoreMedicine +7

Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer

Elisabetta Munzone, Franco Nolè, Aron Goldhirsch, +9

Clinical Breast Cancer

Her2 StatusAdvanced Breast CancerOncologyBreast OncologyMedicine +8

PARP Inhibitors for Breast Cancer Treatment

Stefania Morganti, Antonio Marra, Carmine De Angelis, +12

JAMA Oncology

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

Edoardo Botteri, Maria Teresa Sandri, Vincenzo Bagnardi, +12

Breast Cancer Research and Treatment

Metastatic Breast CancerBreast OncologyTumour Cells NumberTumor HeterogeneityMedicine +6

Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer

Angela Espósito

ecancermedicalscience

Surgical OncologyBreast OncologyCancer ManagementPrognosisPathology +15

Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer

Elisabetta Munzone, Edoardo Botteri, Maria Teresa Sandri, +10

Clinical Breast Cancer

Prognostic BiomarkersAdvanced Breast CancerBreast OncologyMedicineCirculating Tumor Cells +7

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial

Emilia Montagna, Antonella Palazzo, Patrick Maisonneuve, +10

Cancer Letters

Metastatic Breast CancerOncologyBreast OncologyMedicineMetronomic Therapy +8

Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report

Gaetano Aurilio, Elisabetta Munzone, Edoardo Botteri, +9

The Breast Journal

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Matteo Repetto, Edoardo Crimini, Luca Boscolo Bielo, +11

European Journal of Cancer

Year ActivityTumoral PathologyEuropean InstituteMedicineCancer Management +8